H. Hurwitz

THIS PROTEST WILL BE TWEETED

Jennifer Earl, H. Hurwitz, Analicia Mejia Mesinas et al. · Information Communication & Society · 2013 · 207 citations

Communication Activism, Computational Social Science, Social Media +13

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Niharika B. Mettu, Erin Twohy, Fang‐Shu Ou et al. · Annals of Oncology · 2019 · 72 citations

Patient Experience in Virtual Visits Hinges on Technology and the Patient-Clinician Relationship: A Large Survey Study With Open-ended Questions

Susannah Rose, H. Hurwitz, Mary Beth Mercer et al. · Journal of Medical Internet Research · 2021 · 47 citations · Full text

Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC)

J. Hambleton, Jamey Skillings, Fairooz F. Kabbinavar et al. · Journal of Clinical Oncology · 2005 · 41 citations

Bleeding Risk, Pharmacotherapy, Low-dose Asa +21

Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups

G. Fyfe, H. Hurwitz, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2004 · 36 citations

Survival Benefit, Gastrointestinal Oncology, Medicine +15